OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Agreement allows CRO to grow its manufacturing services, including in the chemistry space
Pharmaron Beijing Co., Ltd., a contract research organization (CRO) and R&D service provider based in China, has acquired Aesica Pharmaceuticals Limited’s Cramlington site from Recipharm AB, a contract development and manufacturing organization (CDMO).
The Cramlington site in Newcastle, UK, has a history of current good manufacturing practice (cGMP) manufacturing services for various active pharmaceutical ingredients (APIs), from pilot scale to commercial metric ton scale. According to the CRO, the Cramlington site has more than a 100 cubic meter reactor commercial capacity, and has been inspected and approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), FDA and other regulatory authorities.
As a result of the deal, Pharmaron is able to grow its chemistry and manufacturing services, which is a key component of its fully integrated platform. The integration of the Cramlington site with Pharmaron’s current service capabilities of discovery, process development and early-stage cGMP API manufacturing at Hoddesdon (England) will therefore allow for an end-to-end chemistry and manufacturing service offering in the UK.
“We are delighted to have the Cramlington site join the Pharmaron Group,” comments Boliang Lou, PhD, chairman and CEO of Pharmaron. “This acquisition complements and further enhances Pharmaron’s CMC [chemistry, manufacturing and controls] capabilities in the United Kingdom and China. We are committed to expanding the Cramlington site to meet growing demand.